Premium
Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance
Author(s) -
Blade Joan,
LopezGuillermo Armando,
Rozman Ciril,
Cervantes Francisco,
Salgado Camino,
Aguilar JosepLluis,
VivesCorrons JoanLluis,
Montserrat Emili
Publication year - 1992
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1992.tb08245.x
Subject(s) - monoclonal gammopathy of undetermined significance , medicine , multiple myeloma , amyloidosis , malignant transformation , population , oncology , gastroenterology , pathology , immunology , monoclonal , antibody , monoclonal antibody , environmental health
The actuarial probability of malignant transformation and the impact on expected survival were analysed in a series of 128 persons diagnosed with monoclonal gammopathy of undetermined significance (MGUS) over a 20‐year period. At a median follow‐up of 56 months the M‐component remains stable in 101 patients (78·9%), 14 patients (10·9%) have died from non‐related disorders and 13 (10·2%) have developed malignant transformation of MGUS (multiple myeloma, 10; primary amyloidosis, two; Waldenström's macroglobulinaemia, one). The actuarial probability of malignant transformation at 5 and 10 years was 8·5% and 19·2%, respectively. When different presenting features were analysed for predictive value of the malignant transformation, the IgA type of MGUS was the only variable associated with a higher probability of such an event ( P <0·025). Although no significant difference was observed between the survival probability of persons with MGUS and that of the control population, the development of malignant transformation was associated with a shorter survival ( P <0·001).